Your browser doesn't support javascript.
loading
The receptor binding domain of SARS-CoV-2 spike is the key target of neutralizing antibody in human polyclonal sera.
Tara Steffen; E Taylor Stone; Mariah Hassert; Elizabeth Geerling; Brian T Grimberg; Ana M Espino; Petraleigh Pantoja; Consuelo Climent; Daniel F Hoft; Sarah L George; Carlos A Sariol; Amelia K Pinto; James D Brien.
Afiliação
  • Tara Steffen; Saint Louis University
  • E Taylor Stone; Saint Louis University
  • Mariah Hassert; Saint Louis University
  • Elizabeth Geerling; Saint Louis University
  • Brian T Grimberg; Case Western Reserve University
  • Ana M Espino; University of Puerto Rico
  • Petraleigh Pantoja; University of Puerto Rico
  • Consuelo Climent; University of Puerto Rico
  • Daniel F Hoft; Saint Louis University
  • Sarah L George; Saint Louis University
  • Carlos A Sariol; University of Puerto Rico, Medical Sciences Campus
  • Amelia K Pinto; Saint Louis University
  • James D Brien; Saint Louis University
Preprint em Inglês | bioRxiv | ID: ppbiorxiv-261727
ABSTRACT
Natural infection of SARS-CoV-2 in humans leads to the development of a strong neutralizing antibody response, however the immunodominant targets of the polyclonal neutralizing antibody response are still unknown. Here, we functionally define the role SARS-CoV-2 spike plays as a target of the human neutralizing antibody response. In this study, we identify the spike protein subunits that contain antigenic determinants and examine the neutralization capacity of polyclonal sera from a cohort of patients that tested qRT-PCR-positive for SARS-CoV-2. Using an ELISA format, we assessed binding of human sera to spike subunit 1 (S1), spike subunit 2 (S2) and the receptor binding domain (RBD) of spike. To functionally identify the key target of neutralizing antibody, we depleted sera of subunit-specific antibodies to determine the contribution of these individual subunits to the antigen-specific neutralizing antibody response. We show that epitopes within RBD are the target of a majority of the neutralizing antibodies in the human polyclonal antibody response. These data provide critical information for vaccine development and development of sensitive and specific serological testing.
Licença
cc_no
Texto completo: Disponível Coleções: Preprints Base de dados: bioRxiv Tipo de estudo: Cohort_studies / Estudo observacional / Estudo prognóstico Idioma: Inglês Ano de publicação: 2020 Tipo de documento: Preprint
Texto completo: Disponível Coleções: Preprints Base de dados: bioRxiv Tipo de estudo: Cohort_studies / Estudo observacional / Estudo prognóstico Idioma: Inglês Ano de publicação: 2020 Tipo de documento: Preprint
...